This stimulation of angiogenesis by the cancer-derived exosomes was found to be mediated in a Src-dependent fashion, as dasatinib, a known Src-family kinase inhibitor, blocked the endothelial cell response to cancer exosomes. This evidence concerns the gene SRC and cancer.